Albireo Pharma Inc (ALBO) Gets a Buy Rating from Wedbush

By Jason Carr

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Albireo Pharma Inc (ALBOResearch Report), with a price target of $69. The company’s shares opened today at $23.30.

According to TipRanks.com, Moussatos ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.7% and a 33.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Global Blood Therapeutics.

Albireo Pharma Inc has an analyst consensus of Moderate Buy, with a price target consensus of $50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $39.87 and a one-year low of $19.10. Currently, Albireo Pharma Inc has an average volume of 39.08K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384.